Psychopharmacologic Drugs : Affective Disorders
OVALD1 “Valdoxan FC tablet” 25 mg/tab
適應症：成人重鬱症。
Usual dose:
25 mg orally at bedtime; if no response after 2 weeks, may increase to 50 mg orally at bedtime for at least 6 months duration, no dosage taper necessary upon discontinuation.
Dose adjustment:
Hepatic impairment, including cirrhosis or active liver disease, or transaminases exceeding 3 times ULN: use is contraindicated.
Geriatric: dosage adjustments are not required in patients 74 years or younger; use not recommended in patients 75 years or older.
Contraindication:
Concomitant use of potent CYP1A2 inhibitors (eg, fluvoxamine, ciprofloxacin).
Hepatic impairment (ie, cirrhosis or active liver disease) or transaminase levels greater than 3 times ULN.
Hypersensitivity to agomelatine or any component of the product .
Adverse effect:
Common: Hyperhidrosis, abdominal pain, constipation, diarrhea, nausea, vomiting , increased liver enzymes, backache, dizziness, headache, insomnia, migraine, somnolence, anxiety, fatigue.
Serious: Hepatitis, jaundice, liver failure, hallucinations.
健保給付規範：同fluoxetine.